# Lichen Planus Pigmentosus Localized to the Glans Penis: A Rare Presentation Treated With Ruxolitinib

**Authors:** Sanjidah Ira, Hannah Kopelman, William Steffes

PMC · DOI: 10.7759/cureus.102909 · 2026-02-03

## TL;DR

A rare case of lichen planus pigmentosus on the penis in a young man showed some improvement with ruxolitinib, a new treatment option.

## Contribution

This is the first reported case of genital LPP treated with topical ruxolitinib, suggesting a novel therapeutic approach.

## Key findings

- LPP localized to the glans penis is a rare presentation with no prior documented cases.
- Topical ruxolitinib showed subtle improvement in treatment-resistant genital LPP.
- JAK inhibitors may offer a novel therapeutic option for lichen-planus-associated pigmentary disorders.

## Abstract

Lichen planus pigmentosus (LPP) is a rare variant of lichen planus characterized by macules of black or dark brown color distributed in the sun-exposed areas of the body. It is common among individuals with darker skin, with cases reported in the Middle East, Korea, Japan, and Latin America. Genital involvement is rare, with no reported cases describing isolated penile disease. Management of genital LPP is also challenging due to the sensitive nature of the skin and the associated risks of long-term topical corticosteroid use. We report a case of a 24-year-old male presenting with asymptomatic hyperpigmented lesions localized to the dorsal penile shaft, diagnosed as LPP on histopathology. The patient demonstrated minimal response to prior therapies, including topical corticosteroids and topical calcineurin inhibitors (TCIs). Given treatment resistance, topical ruxolitinib was initiated, with subtle improvement. This case highlights a rare anatomic presentation of LPP and explores the potential role of topical JAK inhibitors as a novel therapeutic option for lichen-planus-associated pigmentary disorders.

## Linked entities

- **Chemicals:** ruxolitinib (PubChem CID 17754772)
- **Diseases:** lichen planus pigmentosus (MONDO:0016774), lichen planus (MONDO:0006572)

## Full-text entities

- **Genes:** JAK1 (Janus kinase 1) [NCBI Gene 3716] {aka AIIDE, JAK1A, JAK1B, JTK3}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}
- **Diseases:** LPP (MESH:D008010), hyperpigmented lesion (MESH:C537836), penile melanosis (MESH:D008548), FDE (MESH:D003875), infections (MESH:D007239), COVID-19 (MESH:D000086382), balanitis (MESH:D001446), penile disease (MESH:D010409), pigmented contact dermatitis (MESH:D003877), pigment incontinence (MESH:D014549), atopic dermatitis (MESH:D003876), necrotic (MESH:D009336), hyperplasia (MESH:D006965), genital herpes (MESH:D006558), EDP (MESH:D004890), Inflammation (MESH:D007249), lichenoid (MESH:D017512), pain (MESH:D010146), ashy dermatosis (MESH:D012871), Genital hyperpigmentation (MESH:D017495), irritation (MESH:D001523), macular pigmentation (MESH:D010859), vitiligo (MESH:D014820), atrophic (MESH:D020966), atrophy (MESH:D001284), lichenoid dermatitis (MESH:D003872), acanthosis (MESH:D000052), pigmentary disorder (MESH:C535508), dysuria (MESH:D053159), itching (MESH:D011537)
- **Chemicals:** LPP (-), H&amp;E (MESH:D006371), tacrolimus (MESH:D016559), hematoxylin (MESH:D006416), steroid (MESH:D013256), minocycline (MESH:D008911), melanin (MESH:D008543), eosin (MESH:D004801), kojic acid (MESH:C011890), betamethasone (MESH:D001623), hydrocortisone (MESH:D006854), hydroquinone (MESH:C031927), ketoconazole (MESH:D007654), tranexamic acid (MESH:D014148), clotrimazole (MESH:D003022), mometasone (MESH:D000068656), pimecrolimus (MESH:C117268), Ruxolitinib (MESH:C540383)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12962405/full.md

---
Source: https://tomesphere.com/paper/PMC12962405